{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:46:30Z","timestamp":1782870390173,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Science and Technology Program of theJiangxi Provincial Health Commission","award":["202210041"],"award-info":[{"award-number":["202210041"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Backgrounds<\/jats:title>\n                    <jats:p>Syndecan-1 (SDC1) is a key transmembrane proteoglycan involved in cell adhesion and epithelial integrity. Although evidence links SDC1 to tumor progression, its pan-cancer functions and mechanistic roles are not fully understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We defined the multidimensional role of SDC1 across cancers by leveraging multi-platform genomic and clinical data. Our study characterized its associations with patient survival, molecular mechanisms, immune contexture, and therapeutic sensitivity. Initial observations in glioma subtypessuggested a pro-tumorigenic function. Consequently, this functional role in glioblastoma (GBM) was empirically validated through a combination of cellular-level assays and animal xenograft models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SDC1 expression was upregulated in numerous cancer types, correlating with poorer survival rates among patients. Receiver operating characteristic (ROC) analyses confirmed its robust diagnostic value across malignancies. Notably, a notable correlation was identified between SDC1 levels and key components within the tumor microenvironment, including CD4+\/CD8\u2009+\u2009T lymphocytes, cancer-associated fibroblasts (CAFs), and myeloid-derived suppressor cells (MDSCs). Functional assays revealed that SDC1 depletion markedly attenuated GBM cell proliferation and migration. Subsequently, the capacity for migration and tissue invasion was assessed using both experimental and animal model systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Integrated bioinformatic and experimental analyses identify SDC1 as a pan-cancer biomarker with particular clinical significance in GBM. Its expression correlates with immune infiltration patterns, positioning SDC1 as a promising diagnostic and immunotherapeutic target.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12672-026-05172-0","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T18:34:18Z","timestamp":1778178858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated pan-cancer analysis and experimental validation reveal that syndecan-1 drives glioblastoma pathogenesis and associates with immune infiltration"],"prefix":"10.1007","volume":"17","author":[{"given":"Qing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqian","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunjian","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"10","key":"5172_CR1","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1097\/cm9.0000000000003619","volume":"138","author":"Y Wu","year":"2025","unstructured":"Wu Y, He S, Cao M, Teng Y, Li Q, Tan N, Wang J, Zuo T, Li T, Zheng Y, Xia C, Chen W. Corrigendum: Comparative analysis of cancer statistics in China and the United States in 2024. Chin Med J (Engl). 2025;138(10):1260. https:\/\/doi.org\/10.1097\/cm9.0000000000003619.","journal-title":"Chin Med J (Engl)"},{"key":"5172_CR2","doi-asserted-by":"publisher","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024, CA Cancer J Clin 74(1) (2024) 12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","DOI":"10.3322\/caac.21820"},{"issue":"1","key":"5172_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/febs.13940","volume":"284","author":"NA Afratis","year":"2017","unstructured":"Afratis NA, Nikitovic D, Multhaupt HA, Theocharis AD, Couchman JR, Karamanos NK. Syndecans - key regulators of cell signaling and biological functions. Febs j. 2017;284(1):27\u201341. https:\/\/doi.org\/10.1111\/febs.13940.","journal-title":"Febs j"},{"issue":"15","key":"5172_CR4","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1111\/febs.14828","volume":"286","author":"F Gondelaud","year":"2019","unstructured":"Gondelaud F, Ricard-Blum S. Structures and interactions of syndecans. Febs j. 2019;286(15):2994\u20133007. https:\/\/doi.org\/10.1111\/febs.14828.","journal-title":"Febs j"},{"issue":"2","key":"5172_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1016-8478(23)07324-7","volume":"24","author":"AH Bartlett","year":"2007","unstructured":"Bartlett AH, Hayashida K, Park PW. Molecular and Cellular Mechanisms of Syndecans in Tissue Injury and Inflammation. Mol Cells. 2007;24(2):153\u201366. https:\/\/doi.org\/10.1016\/S1016-8478(23)07324-7.","journal-title":"Mol Cells"},{"issue":"2","key":"5172_CR6","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/febs.15356","volume":"288","author":"S Kumar Katakam","year":"2021","unstructured":"Kumar Katakam S, Tria V, Sim WC, Yip GW, Molgora S, Karnavas T, Elghonaimy EA, Pelucchi P, Piscitelli E, Ibrahim SA, Zucchi I, Reinbold R, Greve B, G\u00f6tte M. The heparan sulfate proteoglycan syndecan-1 regulates colon cancer stem cell function via a focal adhesion kinase-Wnt signaling axis. Febs j. 2021;288(2):486\u2013506. https:\/\/doi.org\/10.1111\/febs.15356.","journal-title":"Febs j"},{"issue":"1","key":"5172_CR7","doi-asserted-by":"publisher","first-page":"C29","DOI":"10.1152\/ajpcell.00024.2022","volume":"323","author":"Z Yang","year":"2022","unstructured":"Yang Z, Chen S, Ying H, Yao W. Targeting syndecan-1: new opportunities in cancer therapy. Am J Physiol Cell Physiol. 2022;323(1):C29\u201345. https:\/\/doi.org\/10.1152\/ajpcell.00024.2022.","journal-title":"Am J Physiol Cell Physiol"},{"key":"5172_CR8","doi-asserted-by":"publisher","unstructured":"Bezborodova OA, Trunova GV, Nemtsova ER, Khokhlova VA, Venediktova JB, Morozova NB, Vorontsova MS, Plyutinskaya AD, Zharova EP, Shegai PV, Kaprin AD. Targets for CAR Therapy in Multiple Myeloma. Int J Mol Sci. 2025;26(13). https:\/\/doi.org\/10.3390\/ijms26136051.","DOI":"10.3390\/ijms26136051"},{"issue":"13","key":"5172_CR9","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood.2020008188","volume":"137","author":"Z Ren","year":"2021","unstructured":"Ren Z, Spaargaren M, Pals ST. Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis. Blood. 2021;137(13):1713\u20138. https:\/\/doi.org\/10.1182\/blood.2020008188.","journal-title":"Blood"},{"issue":"7752","key":"5172_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-019-1062-1","volume":"568","author":"W Yao","year":"2019","unstructured":"Yao W, Rose JL, Wang W, Seth S, Jiang H, Taguchi A, Liu J, Yan L, Kapoor A, Hou P, Chen Z, Wang Q, Nezi L, Xu Z, Yao J, Hu B, Pettazzoni PF, Ho IL, Feng N, Ramamoorthy V, Jiang S, Deng P, Ma GJ, Den P, Tan Z, Zhang SX, Wang H, Wang YA, Deem AK, Fleming JB, Carugo A, Heffernan TP, Maitra A, Viale A, Ying H, Hanash S, DePinho RA, Draetta GF. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature. 2019;568(7752):410\u20134. https:\/\/doi.org\/10.1038\/s41586-019-1062-1.","journal-title":"Nature"},{"issue":"10","key":"5172_CR11","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/1878-0261.13667","volume":"18","author":"HR Yen","year":"2024","unstructured":"Yen HR, Liao WC, Chen CH, Su YA, Huang YW, Hsiao C, Chou YL, Chu YH, Shih PK, Liu CH. Targeting chondroitin sulfate suppresses macropinocytosis of breast cancer cells by modulating syndecan-1 expression. Mol Oncol. 2024;18(10):2569\u201385. https:\/\/doi.org\/10.1002\/1878-0261.13667.","journal-title":"Mol Oncol"},{"issue":"11","key":"5172_CR12","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.7150\/thno.81999","volume":"13","author":"L Zeng","year":"2023","unstructured":"Zeng L, Zheng W, Liu X, Zhou Y, Jin X, Xiao Y, Bai Y, Pan Y, Zhang J, Shao C. SDC1-TGM2-FLOT1-BHMT complex determines radiosensitivity of glioblastoma by influencing the fusion of autophagosomes with lysosomes. Theranostics. 2023;13(11):3725\u201343. https:\/\/doi.org\/10.7150\/thno.81999.","journal-title":"Theranostics"},{"issue":"3","key":"5172_CR13","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/15548627.2022.2105562","volume":"19","author":"W Zheng","year":"2023","unstructured":"Zheng W, Chen Q, Liu H, Zeng L, Zhou Y, Liu X, Bai Y, Zhang J, Pan Y, Shao C. SDC1-dependent TGM2 determines radiosensitivity in glioblastoma by coordinating EPG5-mediated fusion of autophagosomes with lysosomes. Autophagy. 2023;19(3):839\u201357. https:\/\/doi.org\/10.1080\/15548627.2022.2105562.","journal-title":"Autophagy"},{"issue":"6","key":"5172_CR14","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repe\u010dka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, Zhu J, Haussler D. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675\u20138. https:\/\/doi.org\/10.1038\/s41587-020-0546-8.","journal-title":"Nat Biotechnol"},{"key":"5172_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","volume":"25","author":"DS Chandrashekar","year":"2022","unstructured":"Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, Netto GJ, Qin ZS, Kumar S, Manne U, Creighton CJ, Varambally S. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18\u201327. https:\/\/doi.org\/10.1016\/j.neo.2022.01.001.","journal-title":"Neoplasia"},{"key":"5172_CR16","doi-asserted-by":"publisher","first-page":"W283","DOI":"10.1093\/nar\/gkaf423","volume":"53W1","author":"YJ Kang","year":"2025","unstructured":"Kang YJ, Pan L, Liu Y, Rong Z, Liu J, Liu F, GEPIA3. Enhanced drug sensitivity and interaction network analysis for cancer research. Nucleic Acids Res. 2025;53W1:W283\u201390. https:\/\/doi.org\/10.1093\/nar\/gkaf423.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"5172_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.Cd-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134. https:\/\/doi.org\/10.1158\/2159-8290.Cd-12-0095.","journal-title":"Cancer Discov"},{"issue":"1","key":"5172_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/pro.3307","volume":"27","author":"PJ Thul","year":"2018","unstructured":"Thul PJ, Lindskog C. The human protein atlas: a spatial map of the human proteome. Protein Sci. 2018;27(1):233\u201344. https:\/\/doi.org\/10.1002\/pro.3307.","journal-title":"Protein Sci"},{"issue":"D1","key":"5172_CR19","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, Gable AL, Fang T, Doncheva NT, Pyysalo S, Bork P, Jensen LJ, von Mering C. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638\u201346. https:\/\/doi.org\/10.1093\/nar\/gkac1000.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"5172_CR20","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16(5):284\u20137. https:\/\/doi.org\/10.1089\/omi.2011.0118.","journal-title":"Omics"},{"issue":"20","key":"5172_CR21","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1093\/bioinformatics\/btz210","volume":"35","author":"B Ru","year":"2019","unstructured":"Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, Chu KC, Wong CY, Lau CY, Chen I, Chan NW, Zhang J. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200\u20132. https:\/\/doi.org\/10.1093\/bioinformatics\/btz210.","journal-title":"Bioinformatics"},{"key":"5172_CR22","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48W1","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48W1:W509\u201314. https:\/\/doi.org\/10.1093\/nar\/gkaa407.","journal-title":"Nucleic Acids Res"},{"issue":"21","key":"5172_CR23","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1093\/bioinformatics\/bty411","volume":"34","author":"C-J Liu","year":"2018","unstructured":"Liu C-J, Hu F-F, Xia M-X, Han L, Zhang Q, Guo A-Y. GSCALite: a web server for gene set cancer analysis. Bioinformatics. 2018;34(21):3771\u20132. https:\/\/doi.org\/10.1093\/bioinformatics\/bty411.","journal-title":"Bioinformatics"},{"issue":"1","key":"5172_CR24","doi-asserted-by":"publisher","first-page":"152756","DOI":"10.1016\/j.prp.2019.152756","volume":"216","author":"S Liao","year":"2020","unstructured":"Liao S, Liu C, Zhu G, Wang K, Yang Y, Wang C. Relationship between SDC1 and cadherin signalling activation in cancer. Pathol Res Pract. 2020;216(1):152756. https:\/\/doi.org\/10.1016\/j.prp.2019.152756.","journal-title":"Pathol Res Pract"},{"key":"5172_CR25","doi-asserted-by":"publisher","first-page":"1014638","DOI":"10.3389\/fimmu.2022.1014638","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhang Y, Zhao L, Wang J, Li J, Wang X, Zhang M, Hu X. Exploitation of tumor antigens and construction of immune subtype classifier for mRNA vaccine development in bladder cancer. Front Immunol. 2022;13:1014638. https:\/\/doi.org\/10.3389\/fimmu.2022.1014638.","journal-title":"Front Immunol"},{"issue":"2","key":"5172_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10549-020-05954-2","volume":"185","author":"M Sadeghalvad","year":"2021","unstructured":"Sadeghalvad M, Mohammadi-Motlagh HR, Rezaei N. Immune microenvironment in different molecular subtypes of ductal breast carcinoma. Breast Cancer Res Treat. 2021;185(2):261\u201379. https:\/\/doi.org\/10.1007\/s10549-020-05954-2.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"5172_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.cell.2016.01.021","volume":"165","author":"R Basu","year":"2016","unstructured":"Basu R, Whitlock BM, Husson J, Le Floc\u2019h A, Jin W, Oyler-Yaniv A, Dotiwala F, Giannone G, Hivroz C, Biais N, Lieberman J, Kam LC, Huse M. Cytotoxic T Cells Use Mechanical Force to Potentiate Target Cell Killing. Cell. 2016;165(1):100\u201310. https:\/\/doi.org\/10.1016\/j.cell.2016.01.021.","journal-title":"Cell"},{"issue":"1","key":"5172_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/cmi.2011.45","volume":"9","author":"C Gordy","year":"2012","unstructured":"Gordy C, He YW. Endocytosis by target cells: an essential means for perforin- and granzyme-mediated killing. Cell Mol Immunol. 2012;9(1):5\u20136. https:\/\/doi.org\/10.1038\/cmi.2011.45.","journal-title":"Cell Mol Immunol"},{"key":"5172_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev-immunol-101220-015603","volume":"40","author":"SM Downs-Canner","year":"2022","unstructured":"Downs-Canner SM, Meier J, Vincent BG, Serody JS. B Cell Function in the Tumor Microenvironment. Annu Rev Immunol. 2022;40:169\u201393. https:\/\/doi.org\/10.1146\/annurev-immunol-101220-015603.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"5172_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13046-024-03050-7","volume":"43","author":"S Wang","year":"2024","unstructured":"Wang S, Li J, Hong S, Wang N, Xu S, Yang B, Zheng Y, Zhang J, Pan B, Hu Y, Wang Z. Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM\/PD-L1 signaling. J Exp Clin Cancer Res. 2024;43(1):121. https:\/\/doi.org\/10.1186\/s13046-024-03050-7.","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"5172_CR31","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1208\/s12249-020-01856-0","volume":"21","author":"Z Wang","year":"2020","unstructured":"Wang Z, Yang J, Yang Y, Pu X, Zhao J, Zhang N. Targeted and Combined TPCA-1-Gold Nanocage Therapy for In Vivo Treatment of Inflammatory Arthritis. AAPS PharmSciTech. 2020;21(8):298. https:\/\/doi.org\/10.1208\/s12249-020-01856-0.","journal-title":"AAPS PharmSciTech"},{"key":"5172_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jare.2024.12.026","volume":"76","author":"S Wang","year":"2025","unstructured":"Wang S, Zhang X, Chen Q, Wu H, Cao S, Zhao S, Li G, Wang J, Gong Y, Wang X, Pang D, Gao S. FTO activates PD-L1 promotes immunosuppression in breast cancer via the m6A\/YTHDF3\/PDK1 axis under hypoxic conditions. J Adv Res. 2025;76:191\u2013206. https:\/\/doi.org\/10.1016\/j.jare.2024.12.026.","journal-title":"J Adv Res"},{"key":"5172_CR33","doi-asserted-by":"publisher","unstructured":"Park K, Tan EH, O\u2019Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, K\u00f6lbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V. Paz-Ares, Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5). https:\/\/doi.org\/10.1016\/s1470-2045(16)30033-x. 577\u2009\u2013\u200989.","DOI":"10.1016\/s1470-2045(16)30033-x"},{"issue":"1","key":"5172_CR34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41392-025-02149-3","volume":"10","author":"X Hu","year":"2025","unstructured":"Hu X, Zhang Q, Wang L, Zhang J, Ouyang Q, Wang X, Li W, Xie W, Tong Z, Wang S, Xu F, Sun T, Liu W, Chen Z, Wu J, Wang Y, Wang H, Yan M, Wang X, Wang J, Cao F, Du Y, Zhang Y, Chen L, Lu P, Sun S, Zhang R, Zang A, Nie X, Lei Y. ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer. Signal Transduct Target Ther. 2025;10(1):56. https:\/\/doi.org\/10.1038\/s41392-025-02149-3.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"5172_CR35","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/neuonc\/noad224","volume":"26","author":"JEC Bromberg","year":"2024","unstructured":"Bromberg JEC, Issa S, van der Holt B, van der Meulen M, Dirven L, Minnema MC, Seute T, Durian M, Cull G, van der Poel MWM, Stevens WBC, Zijlstra JM, Brandsma D, Nijland M, Mason KD, Beeker A, Abrahamse-Testroote MCJ, van den Bent MJ, de Jong D, Doorduijn JK. Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105\/ALLG NHL 24 study. Neuro Oncol. 2024;26(4):724\u201334. https:\/\/doi.org\/10.1093\/neuonc\/noad224.","journal-title":"Neuro Oncol"},{"issue":"8","key":"5172_CR36","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1021\/acsptsci.5c00308","volume":"8","author":"N Han","year":"2025","unstructured":"Han N, Hu J, Xie ZX, Zhang L, Li LG, Yu XR, Kong C, Leng F, Hu C, Zhang Q, Wang MF, Li TF. Teniposide Triggers DNA Repair Inhibition by Binding and Ubiquitination of Apurinic\/Apyrimidinic Endonuclease 1 to Boost Oxidative DNA Damage for Lung Cancer Destruction. ACS Pharmacol Transl Sci. 2025;8(8):2710\u201324. https:\/\/doi.org\/10.1021\/acsptsci.5c00308.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"11","key":"5172_CR37","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1136\/jnis-2023-021055","volume":"16","author":"J Ruan","year":"2024","unstructured":"Ruan J, Shi Y, Luo P, Li L, Huang J, Chen J, Yang H. Safety and feasibility of intra-arterial delivery of teniposide to high grade gliomas after blood-brain barrier disruption: a case series. J Neurointerv Surg. 2024;16(11):1152\u20136. https:\/\/doi.org\/10.1136\/jnis-2023-021055.","journal-title":"J Neurointerv Surg"},{"key":"5172_CR38","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/ijn.S441135","volume":"19","author":"C Peng","year":"2024","unstructured":"Peng C, Xu Y, Wu J, Wu D, Zhou L, Xia X. TME-Related Biomimetic Strategies Against Cancer. Int J Nanomed. 2024;19:109\u201335. https:\/\/doi.org\/10.2147\/ijn.S441135.","journal-title":"Int J Nanomed"},{"issue":"11","key":"5172_CR39","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662\u201380. https:\/\/doi.org\/10.1038\/s41568-020-0285-7.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"5172_CR40","doi-asserted-by":"publisher","first-page":"e22432","DOI":"10.1016\/j.heliyon.2023.e22432","volume":"9","author":"X Xu","year":"2023","unstructured":"Xu X, Xu Y, Hu W, Hong W, Wang Y, Zhang X, Fan X, Wang T, Lou H, Yang Y, Qian J. Stromal score is a promising index in tumor patients\u2019 outcome determination. Heliyon. 2023;9(11):e22432. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e22432.","journal-title":"Heliyon"},{"key":"5172_CR41","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, Trevi\u00f1o V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, Mills GB, Verhaak RG. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. https:\/\/doi.org\/10.1038\/ncomms3612.","journal-title":"Nat Commun"},{"issue":"4","key":"5172_CR42","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1089\/wound.2014.0555","volume":"4","author":"MA Stepp","year":"2015","unstructured":"Stepp MA, Pal-Ghosh S, Tadvalkar G, Pajoohesh-Ganji A. Syndecan-1 and its expanding list of contacts. Adv Wound Care. 2015;4(4):235\u201349. https:\/\/doi.org\/10.1089\/wound.2014.0555.","journal-title":"Adv Wound Care"},{"key":"5172_CR43","doi-asserted-by":"publisher","unstructured":"Couchman JR. Syndecan-1 (CD138), Carcinomas and EMT. Int J Mol Sci. 2021;22(8). https:\/\/doi.org\/10.3390\/ijms22084227.","DOI":"10.3390\/ijms22084227"},{"key":"5172_CR44","doi-asserted-by":"publisher","first-page":"784983","DOI":"10.3389\/fcell.2021.784983","volume":"9","author":"S Guo","year":"2021","unstructured":"Guo S, Wu X, Lei T, Zhong R, Wang Y, Zhang L, Zhao Q, Huang Y, Shi Y, Wu L. The role and therapeutic value of syndecan-1 in cancer metastasis and drug resistance. Front Cell Dev Biol. 2021;9:784983. https:\/\/doi.org\/10.3389\/fcell.2021.784983.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"5172_CR45","doi-asserted-by":"publisher","first-page":"18727","DOI":"10.1038\/s41598-023-44646-x","volume":"13","author":"CL Zhang","year":"2023","unstructured":"Zhang CL, Shen Q, Liu FD, Yang F, Gao MQ, Jiang XC, Li Y, Zhang XY, En GE, Pan X, Pang B. SDC1 and ITGA2 as novel prognostic biomarkers for PDAC related to IPMN. Sci Rep. 2023;13(1):18727. https:\/\/doi.org\/10.1038\/s41598-023-44646-x.","journal-title":"Sci Rep"},{"issue":"10","key":"5172_CR46","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1158\/1078-0432.Ccr-18-2946","volume":"25","author":"V Indira Chandran","year":"2019","unstructured":"Indira Chandran V, Welinder C, M\u00e5nsson AS, Offer S, Freyhult E, Pernemalm M, Lund SM, Pedersen S, Lehti\u00f6 J, Marko-Varga G, Johansson MC, Englund E, Sundgren PC, Belting M. Ultrasensitive Immunoprofiling of Plasma Extracellular Vesicles Identifies Syndecan-1 as a Potential Tool for Minimally Invasive Diagnosis of Glioma. Clin Cancer Res. 2019;25(10):3115\u201327. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-2946.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5172_CR47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11060-005-9010-3","volume":"77","author":"A Watanabe","year":"2006","unstructured":"Watanabe A, Mabuchi T, Satoh E, Furuya K, Zhang L, Maeda S, Naganuma H. Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas:: participation of nuclear factor-\u03baB in upregulation of syndecan-1 expression. J Neurooncol. 2006;77(1):25\u201332. https:\/\/doi.org\/10.1007\/s11060-005-9010-3.","journal-title":"J Neurooncol"},{"key":"5172_CR48","doi-asserted-by":"publisher","unstructured":"Nassar E, Hassan N, El-Ghonaimy EA, Hassan H, Abdullah MS, Rottke TV, Kiesel L, Greve B, Ibrahim SA, G\u00f6tte M. Syndecan-1 Promotes Angiogenesis in Triple-Negative Breast Cancer through the Prognostically Relevant Tissue Factor Pathway and Additional Angiogenic Routes. Cancers (Basel). 2021;13(10). https:\/\/doi.org\/10.3390\/cancers13102318.","DOI":"10.3390\/cancers13102318"},{"issue":"37","key":"5172_CR49","doi-asserted-by":"publisher","first-page":"eadi7764","DOI":"10.1126\/sciadv.adi7764","volume":"10","author":"Y Liu","year":"2024","unstructured":"Liu Y, Xu C, Zhang L, Xu G, Yang Z, Xiang L, Jiao K, Chen Z, Zhang X, Liu Y. Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy. Sci Adv. 2024;10(37):eadi7764. https:\/\/doi.org\/10.1126\/sciadv.adi7764.","journal-title":"Sci Adv"},{"issue":"1","key":"5172_CR50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/jcmm.12934","volume":"21","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Wang Z, Liu J, Zhang S, Fei J, Li J, Zhang T, Wang J, Park PW, Chen Y. Cell surface-anchored syndecan-1 ameliorates intestinal inflammation and neutrophil transmigration in ulcerative colitis. J Cell Mol Med. 2017;21(1):13\u201325. https:\/\/doi.org\/10.1111\/jcmm.12934.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"5172_CR51","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1038\/s41467-025-57706-9","volume":"16","author":"M Gossez","year":"2025","unstructured":"Gossez M, Vigneron C, Vandermoeten A, Lepage M, Courcol L, Coudereau R, Paidassai H, Jallades L, Lopez J, Kandara K, Ortillon M, Mommert M, Fabri A, Peronnet E, Grosjean C, Buisson M, Lukaszewicz AC, Rimmel\u00e9 T, Argaud L, Cour M, Py BF, Thaunat O, Defrance T, Monneret G, Venet F. PD-L1(+) plasma cells suppress T lymphocyte responses in patients with sepsis and mouse sepsis models. Nat Commun. 2025;16(1):3030. https:\/\/doi.org\/10.1038\/s41467-025-57706-9.","journal-title":"Nat Commun"},{"issue":"11","key":"5172_CR52","doi-asserted-by":"publisher","first-page":"103349","DOI":"10.1016\/j.isci.2021.103349","volume":"24","author":"T Welte","year":"2021","unstructured":"Welte T, Mai J, Zhang Z, Tian S, Zhang G, Xu Y, Zhang L, Chen SS, Wang T, Shen H. A heparan-sulfate-bearing syndecan-1 glycoform is a distinct surface marker for intra-tumoral myeloid-derived suppressor cells. iScience. 2021;24(11):103349. https:\/\/doi.org\/10.1016\/j.isci.2021.103349.","journal-title":"iScience"},{"key":"5172_CR53","doi-asserted-by":"publisher","first-page":"105202","DOI":"10.1016\/j.ebiom.2024.105202","volume":"105","author":"L Roncali","year":"2024","unstructured":"Roncali L, Marionneau-Lambot S, Roy C, Eychenne R, Gouard S, Avril S, Chouin N, Riou J, Allard M, Rousseau A, Gu\u00e9rard F, Hindr\u00e9 F, Ch\u00e9rel M. Garcion, Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female mice. EBioMedicine. 2024;105:105202. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105202.","journal-title":"EBioMedicine"},{"key":"5172_CR54","doi-asserted-by":"publisher","unstructured":"He J, Huang Z, Han L, Gong Y, Xie C. Mechanisms and management of 3rd\u2013generation EGFR\u2013TKI resistance in advanced non\u2013small cell lung cancer (Review). Int J Oncol. 2021;59(5). https:\/\/doi.org\/10.3892\/ijo.2021.5270.","DOI":"10.3892\/ijo.2021.5270"},{"key":"5172_CR55","doi-asserted-by":"publisher","unstructured":"Ibrahim SA, Gadalla R, El-Ghonaimy EA, Samir O, Mohamed HT, Hassan H, Greve B, El-Shinawi M, Mohamed MM, G\u00f6tte M. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6\/STAT3, Notch and EGFR signaling pathways. Mol Cancer. 2017;16. https:\/\/doi.org\/10.1186\/s12943-017-0621-z.","DOI":"10.1186\/s12943-017-0621-z"},{"issue":"12 Suppl 2","key":"5172_CR56","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","volume":"22","author":"QT Ostrom","year":"2020","unstructured":"Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS, Report CBTRUSS. Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013\u20132017. Neuro Oncol. 2020;22(12 Suppl 2):iv1\u201396. https:\/\/doi.org\/10.1093\/neuonc\/noaa200.","journal-title":"Neuro Oncol"},{"key":"5172_CR57","doi-asserted-by":"publisher","first-page":"105780","DOI":"10.1016\/j.phrs.2021.105780","volume":"171","author":"W Wu","year":"2021","unstructured":"Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, Wu Y, Daldrup-Link HE. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021;171:105780. https:\/\/doi.org\/10.1016\/j.phrs.2021.105780.","journal-title":"Pharmacol Res"},{"issue":"7","key":"5172_CR58","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1111\/cas.13635","volume":"109","author":"R Otani","year":"2018","unstructured":"Otani R, Uzuka T, Higuchi F, Matsuda H, Nomura M, Tanaka S, Mukasa A, Ichimura K, Kim P, Ueki K. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis. Cancer Sci. 2018;109(7):2327\u201335. https:\/\/doi.org\/10.1111\/cas.13635.","journal-title":"Cancer Sci"},{"issue":"1","key":"5172_CR59","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00401-018-1849-4","volume":"136","author":"M Shirahata","year":"2018","unstructured":"Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F, Koelsche C, Wefers A, Reinhardt A, Huang K, Sievers P, Shimizu H, Nanjo H, Kobayashi Y, Miyake Y, Suzuki T, Adachi JI, Mishima K, Sasaki A, Nishikawa R, Bewerunge-Hudler M, Ryzhova M, Absalyamova O, Golanov A, Sinn P, Platten M, Jungk C, Winkler F, Wick A, H\u00e4nggi D, Unterberg A, Pfister SM, Jones DTW, van den Bent M, Hegi M, French P, Baumert BG, Stupp R, Gorlia T, Weller M, Capper D, Korshunov A, Herold-Mende C, Wick W, von Louis DN. Deimling, Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol. 2018;136(1):153\u201366. https:\/\/doi.org\/10.1007\/s00401-018-1849-4.","journal-title":"Acta Neuropathol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05172-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05172-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05172-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:01:01Z","timestamp":1782867661000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05172-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5172"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05172-0","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiments conducted in this study received approval from the Institutional Animal Care and Use Committee at Nanchang University and were performed in compliance with established ethical guidelines (Approval No. NCULAE 20221031006). For this orthotopic intracranial tumor model, ethical compliance was ensured by strict adherence to predefined humane endpoint criteria focusing on animal well-being (weight loss\u2009>\u200920%, neurological deficit, or signs of distress), and we confirm that these limits were not exceeded.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"955"}}